Stay updated with breaking news from Patrick Vermersch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.
Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
Sanofi announces that the New England Journal of Medicine has published positive results from a Phase II trial showing that frexalimab significantly slowed disease activity in people with...
Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced dis...